Abstract 569: Dicycloplatin, a platinum compound appears effective in treating prostate cancer

Abstract

Abstract Dicycloplatin (DCP) is a new platinum-based drug developed in China. Due to its special structure, DCP possesses superior stability and water-solubility, compared to cisplatin and carboplatin. Experimental findings in China demonstrate low in vitro cytotoxicity of dicycloplatin against a variety of human cancer cell lines. DCP toxicity profile of 210 mg/kg of LD50 compares favorably to 14.27 mg/kg for cisplatin and 164 mg/kg for carboplatin. In vivo studies indicate that IV administration of 20 mg/kg DCP in rats is followed by 3.64 μg/g of drug distribution in the prostate. Histoculture Drug Response Assay (HDRA) confirms clinical efficacy of chemotherapy for various cancer types, including prostate cancer. Pre-clinical and clinical studies in China suggest that DCP produces fewer side effects with a maximum tolerated dose of 650 mg/m2. Patients with prostate cancer treated by DCP alone demonstrated persistent benefits. In one case, the prostate-specific antigen (PSA) level returned to normal after 5 consecutive dosages of 600mg administered orally every two weeks. No significant side effects were observed. Investigations of molecular mechanisms at WVU, USA suggest that DCP induces gene signature profile in human ovarian cancer cells through mechanisms similar to other platinum drugs. In conclusion, dicycloplatin may be an effective chemotherapeutic agent for patients with prostate cancer and further investigations in animal and preclinical tests are warranted. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 569.